Masso Torrence Wealth Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Masso Torrence Wealth Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$125K	Sell	17,000 -33,000	-66%	-$169K	0.05%	106
2025 Q2	$200K	Buy	50,000 +15,000	+43%	+$54.6K	0.09%	96
2025 Q1	$111K	Buy	35,000 +5,000	+17%	+$23.6K	0.06%	95
2024 Q4	$161K	Buy	30,000 +20,000	+200%	+$149K	0.08%	93
2024 Q3	$52.8K	Hold	10,000	–	–	0.03%	90
2024 Q2	$18.2K	Hold	10,000	–	–	0.01%	92
2024 Q1	$17.8K	Hold	10,000	–	–	0.01%	91
2023 Q4	$17.6K	Hold	10,000	–	–	0.01%	88
2023 Q3	$14.6K	Buy	+10,000	New	+$21.1K	0.01%	82
2022 Q1	–	Sell	-2,731	Closed	-$7K	–	133
2021 Q4	$7K	Buy	+2,731	New	+$10.6K	﹤0.01%	287

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Masso Torrence Wealth Management's CRVS Position: Q3 2025 in Review

Masso Torrence Wealth Management reduced its Corvus Pharmaceuticals (CRVS) stake by 66% in Q3 2025, selling an estimated $169K and leaving 17,000 shares worth $125K. The position accounts for 0.05% of the portfolio, ranked #106.

Masso Torrence Wealth Management first reported a position in CRVS in Q4 2021 and has held it in 10 quarters since. The position peaked at $200K in Q2 2025. 102 funds tracked by Wall St. Rank hold CRVS as of Q3 2025.

Masso Torrence Wealth Management held 17,000 shares of Corvus Pharmaceuticals worth $125K as of Q3 2025.
Masso Torrence Wealth Management sold 33,000 Corvus Pharmaceuticals shares in Q3 2025, an estimated $169K.
Corvus Pharmaceuticals made up 0.05% of Masso Torrence Wealth Management's portfolio in Q3 2025, its #106 holding.
Masso Torrence Wealth Management first reported a position in Corvus Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Masso Torrence Wealth Management's Corvus Pharmaceuticals position peaked at $200K in Q2 2025.
102 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2025.

Based on Masso Torrence Wealth Management's 13F filing for Q3 2025, filed 20 Oct 2025.